AOBiome Therapeutics Announces the Expansion of its Board of Directors

New appointments integrate broad expertise in clinical development, medicine, finance and business management.

News provided by

Aug 06, 2018, 08:00 ET

CAMBRIDGE, Mass., Aug. 6, 2018 /PRNewswire/ -- AOBiome Therapeutics, Inc. ("AOBiome"), a world-leading clinical-stage microbiome company focusing on research and development of therapeutics for inflammatory conditions, central nervous system disorders and other systemic diseases, today announced the expansion of its Board of Directors with the appointments of (i) Professor Klaus Dugi, Executive Vice President and Chief Medical Officer of Ferring Pharmaceuticals, (ii) Dr. Anna Lisa Jenkins, MBBS, FRCP, Chief Executive Officer of PlaqueTec Ltd. and (iii) Mr. Doug Rosefsky, partner of Prudentia Capital S.A.S., as independent non-executive directors. Mr. Rosefsky will lead the audit committee and Dr. Jenkins will lead the remuneration committee.

"We are very excited to announce the additions of Klaus, Anna Lisa and Doug to the AOBiome Board of Directors," said Mr. Todd Krueger, President and Chief Executive Officer of AOBiome. "These industry veterans bring to AOBiome a broad range of expertise in clinical development, medicine, finance and business management experience. We look forward to benefiting from their strategic insights that will be invaluable to the future direction of the Company."

"It is an honor to bring these seasoned veterans to AOBiome at this important time in the Company's expansion," said Dr. Jun Wang, Chairman of the Board of Directors of AOBiome. "With the company rapidly accelerating its innovative Ammonia Oxidizing Bacteria platform across multiple applications, we are that much closer to achieving our long-term goals within the microbiome space."

Professor Klaus Dugi

Dr. Dugi has over 25 years of experience mainly in the field of medicine. Since 2017, Dr. Dugi has served as Executive Vice President and Chief Medical Officer of Ferring Pharmaceuticals, a multinational pharmaceutical company, and continues to serve in these capacities. His responsibilities at Ferring Pharmaceuticals include medical affairs, pharmacovigilance and quality assurance. In addition, he served at Boehringer Ingelheim, a pharmaceutical company, as Country Managing Director of UK and Ireland from 2015 to 2017, as Chief Medical Officer from 2010 to 2015, as Corporate Vice President of Medical Affairs from 2008 to 2009, and as Vice President of Therapeutic Area Metabolic Diseases from 2006 to 2008. His responsibilities at Boehringer Ingelheim included translational medicine and clinical pharmacology, medical affairs and clinical operations. From 2001 to 2002, Dr. Dugi was the attending physician at the medical clinic of Heidelberg University. He conducted basic and applied biomedical research in the field of atherosclerosis, diabetes and lipid metabolism at the National Institutes of Health in Bethesda, Maryland between 1991 and 1996. He is qualified as a professor of medicine at Heidelberg University, Germany, and he teaches internal medicine and endocrinology at the university.

Anna Lisa Jenkins, MBBS, FCRP

Dr. Jenkins, MBBS, FRCP is currently the Chief Executive Officer of PlaqueTec. Prior to joining PlaqueTec, she was Chief Executive Officer of Dimension Therapeutics, a gene therapy company, until Dimension was acquired by Ultragenyx Pharmaceuticals, a biopharmaceutical company, in 2017. From 2011 to 2014, Dr. Jenkins served at Merck Serono, a German pharmaceutical company, first as its Executive Vice President Global Development and Medical, and then as its Head of Global Research and Development. Prior to this, Dr. Jenkins held several roles at Bristol Myers-Squibb, a global biopharmaceutical company, from 1997 to 2011, including as it Senior Vice President and Head of Global Medical Affairs. Earlier in her career, Dr. Jenkins was a medical officer in the British Royal Navy, achieving the rank of surgeon lieutenant commander.

Doug Rosefsky

Mr. Rosefsky has nearly 25 years of experience mainly in the field of finance, accounting and c-level management. Since July 2017, Mr. Rosefsky has been a partner of Prudentia Capital S.A.S., a private equity fund management company based in France, where he is responsible for investment advisory services. From 1999 to 2015, Mr. Rosefsky was a managing director and European executive committee member of Alvarez & Marsal. From 2010 to 2011, he was an advisor to the board of directors of European Gas Limited, S.A., an oil and gas company listed on the Australian Stock Exchange (stock symbol EPG), which was later renamed as Fitzroy River Corporation Limited (stock symbol FZR). From 2005 to 2007, he served as the Chief Financial Officer and subsequently the Chief Executive Officer at North Atlantic Trading Company and North Atlantic Holding Company, both of which were publicly reported companies and are subsidiaries of Turning Point Brands, Inc., which is listed on the New York Stock Exchange (stock symbol TPB).

About Ammonia Oxidizing Bacteria (AOB)
AOBiome's AOB platform includes patented, proprietary, topical and intranasal formulations which incorporate a single strain of AOB, Nitrosomonas eutropha. The platform is designed to repopulate the skin or nasal microbiome with AOB. Once deployed, AOB consume ammonia and produce nitrite and nitric oxide, a signaling molecule known to regulate inflammation and vasodilation.

About AOBiome Therapeutics
AOBiome Therapeutics is a Cambridge, Massachusetts based life sciences company focused on transforming human health by developing microbiome-based therapies for local, intranasal and systemic inflammatory conditions. Founded in 2013 by PatientsLikeMe founder Jamie Heywood and MIT trained chemical engineer David Whitlock, AOBiome is advancing a pipeline of multiple, clinical-stage therapeutic candidates. The company's portfolio includes six clinical-stage programs in the following indications; acne vulgaris, hypertension, eczema (atopic dermatitis), migraine, rosacea, and allergic rhinitis, as well as earlier-stage preclinical programs targeting diverse inflammatory indications. Learn more at www.aobiome.com.

Contacts:

For Media Inquiries:
Ryo Imai
212-213-0006, ext. 315
[email protected]

SOURCE AOBiome Therapeutics